Barclays PLC Exelixis, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Barclays PLC holds 319,589 shares of EXEL stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

319,589

Previous 319,589 -0.0%

Holding current value

$10.5 Million

Previous $8.29 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$21.96 - $27.6 $1.49 Million - $1.87 Million	-67,720 Reduced 17.48%	319,589 $8.29 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $516,961 - $603,121	-25,416 Reduced 6.16%	387,309 $8.7 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $1.67 Million - $1.99 Million	-83,014 Reduced 16.75%	412,725 $9.79 Million
Q4 2023 Feb 15, 2024	BUY	$19.25 - $24.13 $1.81 Million - $2.27 Million	93,892 Added 23.37%	495,739 $11.9 Million
Q3 2023 Nov 07, 2023	SELL	$19.04 - $22.74 $284,419 - $339,690	-14,938 Reduced 3.58%	401,847 $8.78 Million
Q2 2023 Aug 03, 2023	BUY	$18.17 - $20.48 $2.48 Million - $2.79 Million	136,314 Added 48.6%	416,785 $7.96 Million
Q1 2023 May 04, 2023	SELL	$16.3 - $19.41 $2.4 Million - $2.86 Million	-147,413 Reduced 34.45%	280,471 $5.44 Million
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $1.28 Million - $1.49 Million	85,442 Added 24.95%	427,884 $6.87 Million
Q3 2022 Nov 03, 2022	SELL	$15.68 - $22.27 $4.57 Million - $6.49 Million	-291,341 Reduced 45.97%	342,442 $5.37 Million
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $8.97 Million - $11.9 Million	514,103 Added 429.56%	633,783 $13.2 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $762,909 - $1.02 Million	44,798 Added 59.82%	119,680 $2.71 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $1.6 Million - $2.2 Million	-100,728 Reduced 57.36%	74,882 $1.37 Million
Q3 2021 Nov 09, 2021	SELL	$16.3 - $21.14 $3.91 Million - $5.07 Million	-240,049 Reduced 57.75%	175,610 $3.71 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $3.73 Million - $5.31 Million	207,728 Added 99.9%	415,659 $7.57 Million
Q1 2021 May 13, 2021	BUY	$20.53 - $25.22 $3.58 Million - $4.4 Million	174,555 Added 523.0%	207,931 $4.7 Million
Q4 2020 Feb 11, 2021	SELL	$18.39 - $24.8 $1.25 Million - $1.69 Million	-68,186 Reduced 67.14%	33,376 $670,000
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $1.07 Million - $1.39 Million	-51,715 Reduced 33.74%	101,562 $2.48 Million
Q2 2020 Aug 12, 2020	SELL	$16.46 - $27.42 $12.7 Million - $21.2 Million	-773,055 Reduced 83.45%	153,277 $3.64 Million
Q1 2020 May 13, 2020	BUY	$14.46 - $21.8 $7.47 Million - $11.3 Million	516,287 Added 125.91%	926,332 $16 Million
Q4 2019 Feb 10, 2020	BUY	$15.15 - $18.89 $1.47 Million - $1.83 Million	96,912 Added 30.95%	410,045 $7.23 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $2.45 Million - $3.14 Million	138,424 Added 79.23%	313,133 $5.54 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $2.22 Million - $2.9 Million	117,256 Added 204.09%	174,709 $3.73 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $183,318 - $231,580	9,353 Added 19.44%	57,453 $1.37 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $1.75 Million - $2.79 Million	-127,904 Reduced 72.67%	48,100 $946,000
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $698,041 - $985,263	43,985 Added 33.32%	176,004 $3.12 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $1.94 Million - $2.35 Million	-104,715 Reduced 44.23%	132,019 $2.84 Million
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $1.02 Million - $1.46 Million	-45,908 Reduced 16.24%	236,734 $5.24 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $3.21 Million - $4.09 Million	132,370 Added 88.09%	282,642 $8.59 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $3.51 Million - $4.39 Million	150,272	150,272 $3.64 Million

Others Institutions Holding EXEL

# of Institutions

518

Shares Held

243M

Call Options Held

2.84M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account